Our review revealed a great heterogeneity in definition , format , and values of what is considered a clinical ly relevant difference in pain in RCTs of analgesics , and st and ardizations are advisable
OBJECTIVE To describe the  pain decrease considered as clinical ly relevant when design ing a trial and reporting its results .
Intravenous Regional Anesthesia Using Lidocaine and Magnesium
We conducted this study to evaluate the effects of magnesium , when added to lidocaine for IV regional anesthesia ( IVRA ) , on tourniquet pain . Thirty patients undergoing elective h and surgery during IVRA were r and omly assigned to two groups . IVRA was achieved with 10 mL of saline plus 3 mg/kg lidocaine 0.5 % diluted with saline to a total of 40 mL in group C or with 10 mL of 15 % magnesium sulfate ( 12.4 mmol ) plus 3 mg/kg lidocaine 0.5 % diluted with saline to a total of 40 mL in group M. Injection pain , sensory and motor block onset and recovery time , tourniquet pain , and anesthesia quality were noted . Patients were instructed to receive 75 mg of IM diclofenac when the visual analog scale ( VAS ) score was > 4 , and analgesic requirements were recorded . Sensory and motor block onset times were shorter and recovery times were prolonged in group M ( P < 0.05 ) . VAS scores of tourniquet pain were lower in group M at 15 , 20 , 30 , 40 , and 50 min ( P < 0.001 ) . Anesthesia quality , as determined by the anesthesiologist and surgeon , was better in group M ( P < 0.05 ) . Time to the first postoperative analgesic request in group C was 95 ± 29 min and in group M was 155 ± 38 min ( P < 0.05 ) . Postoperative VAS scores were higher for the first postoperative 6 h in group C ( P <  0.05 ) . Diclofenac consumption was significantly less in group M ( 50 ± 35 mg ) when compared with group C ( 130 + 55 mg ) ( P < 0.05 ) . We conclude that magnesium as an adjunct to lidocaine  improves the quality of anesthesia and analgesia in IVRA
Our review revealed a great heterogeneity in definition , format , and values of what is considered a clinical ly relevant difference in pain in RCTs of analgesics , and st and ardizations are advisable
OBJECTIVE To describe the  pain decrease considered as clinical ly relevant when design ing a trial and reporting its results .